Importer of Controlled Substances; Notice of Application, 14688-14689 [2011-6166]
Download as PDF
<![CDATA[
14688
Federal Register / Vol. 76, No. 52 / Thursday, March 17, 2011 / Notices
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–716]
In the Matter of Certain Large Scale
Integrated Circuit Semiconductor
Chips and Products Containing the
Same; Notice of a Commission
Determination Not To Review an Initial
Determination Terminating the
Investigation; Termination of the
Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has determined not to
review an initial determination (‘‘ID’’)
(Order No. 35) of the presiding
administrative law judge (‘‘ALJ’’)
terminating the above-captioned
investigation based on a settlement
agreement.
SUMMARY:
srobinson on DSKHWCL6B1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Clint Gerdine, Esq., Office of the
General Counsel, U.S. International
Trade Commission, 500 E Street, SW.,
Washington, DC 20436, telephone (202)
708–2310. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street, SW., Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
Internet server at https://www.usitc.gov.
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on May 5, 2010, based on a complaint
filed by Panasonic Corporation of Japan.
75 FR 24742–43. The complaint alleges
violations of section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, in the importation into the United
States, the sale for importation, and the
sale within the United States after
importation of certain large scale
integrated circuit semiconductor chips
and products containing same by reason
of infringement of certain claims of U.S.
Patent Nos. 5,933,364 and 6,834,336.
The complaint further alleges the
existence of a domestic industry. The
VerDate Mar<15>2010
15:48 Mar 16, 2011
Jkt 223001
Commission’s notice of investigation
named several respondents including
the following: Freescale Semiconductor
Xiqing Integrated Semiconductor
Manufacturing Site (‘‘Freescale Xiqing’’)
of China; Freescale Semiconductor
Innovation Center (‘‘Freescale
Innovation’’) of China; Freescale
Semiconductor Pte. Ltd. of Singapore;
Premier Farnell Corporation d/b/a
Newark (‘‘Newark’’) of Independence,
Ohio; Freescale Semiconductor, Inc. of
Austin, Texas; Freescale Semiconductor
Japan Ltd. of Japan; Freescale
Semiconductor Malaysia Sdn. Bhd. of
Malaysia; Freescale Semiconductor Pte.
Ltd. of Singapore; Mouser Electronics,
Inc. of Mansfield, Texas; and Motorola
Inc. of Schaumburg, Illinois.
On August 16, 2010, the Commission
issued notice of its determination not to
review the ALJ’s ID granting
complainant’s unopposed motion to
amend the complaint and notice of
investigation. The notice of
investigation was amended to substitute
Freescale Qiangxin (Tianjin) IC Design
Co., Ltd. of China; Freescale
Semiconductor (China) Limited of
China; and Newark Electronics
Corporation and Newark Corporation of
Chicago, Illinois for respondents
Freescale Xiqing, Freescale Innovation,
and Newark, respectively. 75 FR 51843
(August 23, 2010).
On February 11 and 16, 2011,
respectively, complainant and
respondents filed a joint motion, and a
supplemental joint motion, to terminate
the investigation as to all respondents
based on a settlement agreement. The
Commission investigative attorney filed
a response in support of the motion.
The ALJ issued the subject ID on
February 28, 2011, granting the motion
for termination. He found that the
motion for termination satisfies
Commission rule 210.21(b). He further
found, pursuant to Commission rule
210.50(b)(2), that termination of this
investigation by settlement agreement is
in the public interest. No party
petitioned for review of the ID. The
Commission has determined not to
review the ID, and the investigation is
terminated.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended, 19 U.S.C. 1337, and in
sections 210.21 and 210.42(h) of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.21, 210.42(h).
By order of the Commission.
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
Issued: March 11, 2011.
William R. Bishop,
Acting Secretary to the Commission.
[FR Doc. 2011–6141 Filed 3–16–11; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to Title 21 of the Code of
Federal Regulations § 1301.34(a), this is
notice that on May 6, 2010, Aptuit,
10245 Hickman Mills Drive, Kansas
City, Missouri 64137, made application
by renewal to the Drug Enforcement
Administration (DEA) for registration as
an importer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Marihuana (7360) .........................
Poppy Straw Concentrate (9670)
Schedule
I
II
The company plans to import a
finished pharmaceutical product
containing cannabis extracts in dosage
form for packaging for a clinical trial
study. In addition, the company also
plans to import an ointment for the
treatment of wounds which contain
trace amounts of the controlled
substances normally found in poppy
straw concentrate for packaging and
labeling for clinical trials.
No comments, objections, or requests
for any hearings will be accepted on any
application for registration or reregistration to import crude opium,
poppy straw, concentrate of poppy
straw or coca leaves. As explained in
the Correction to Notice of Application
pertaining to Rhodes Technologies, 72
FR 3417 (2007), comments and requests
for hearings on applications to import
narcotic raw material are not
appropriate.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
E:\FR\FM\17MRN1.SGM
17MRN1
Federal Register / Vol. 76, No. 52 / Thursday, March 17, 2011 / Notices
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than April 15, 2011.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: March 8, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Meridian Medical Technologies to
import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
Meridian Medical Technologies to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: March 9, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–6166 Filed 3–16–11; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2011–6165 Filed 3–16–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
14689
company to export domesticallymanufactured FDF to foreign markets.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Mylan Pharmaceuticals, Inc. to import
the basic classes of controlled
substances is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
Mylan Pharmaceuticals, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: March 9, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–6164 Filed 3–16–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Importer of Controlled Substances;
Notice of Registration
srobinson on DSKHWCL6B1PROD with NOTICES
Drug Enforcement Administration
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Importer of Controlled Substances;
Notice of Registration
Drug Enforcement Administration
By Notice dated November 29, 2010,
and published in the Federal Register
on December 9, 2010 (75 FR 76755),
Mylan Pharmaceuticals, Inc., 781
Chestnut Ridge Road, Morgantown,
West Virginia 26505, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the following basic
classes of controlled substances:
Manufacturer of Controlled
Substances; Notice of Application
By Notice dated November 19, 2010,
and published in the Federal Register
on December 3, 2010, 75 FR 75496,
Meridian Medical Technologies, 2555
Hermelin Drive, St. Louis, Missouri
63144, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Morphine (9300), a basic class of
controlled substance listed in schedule
II.
The company manufactures a product
containing morphine in the United
States. The company exports this
product to customers around the world,
including in Europe. The company has
been asked to ensure that its product
sold to European customers meets
standards established by the European
Pharmacopeia, which is administered
by the Directorate for the Quality of
Medicines (EDQM). In order to ensure
that its product will meet European
specifications, the company seeks to
import morphine supplied by EDQM to
use as reference standards. This is the
sole purpose for which the company
will be authorized by DEA to import
morphine.
VerDate Mar<15>2010
15:48 Mar 16, 2011
Jkt 223001
Drug
Schedule
Methylphenidate (1724) .................
Oxycodone (9143) .........................
Hydromorphone (9150) ..................
Fentanyl (9801) ..............................
II
II
II
II
The company plans to import the
listed controlled substances in finished
dosage form (FDF) from foreign sources
for analytical testing and clinical trials
in which the foreign FDF will be
compared to the company’s own
domestically-manufactured FDF. This
analysis is required to allow the
PO 00000
Frm 00043
Fmt 4703
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 9, 2010,
Mallinckrodt, Inc., 3600 North Second
Street, St. Louis, Missouri 63147, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Sfmt 4703
Drug
Tetrahydrocannabinols (7370) .......
Codeine-N-oxide (9053) ................
Dihydromorphine (9145) ................
Difenoxin (9168) ............................
Morphine-N-oxide (9307) ...............
Normorphine (9313) .......................
Norlevorphanol (9634) ...................
Amphetamine (1100) .....................
Methamphetamine (1105) ..............
Methylphenidate (1724) .................
Nabilone (7379) .............................
Codeine (9050) ..............................
Diprenorphine (9058) .....................
Etorphine HCl (9059) .....................
E:\FR\FM\17MRN1.SGM
17MRN1
Schedule
I
I
I
I
I
I
I
II
II
II
II
II
II
II
]]>Agencies
[Federal Register Volume 76, Number 52 (Thursday, March 17, 2011)]
[Notices]
[Pages 14688-14689]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-6166]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to Title 21 of the Code of Federal Regulations Sec.
1301.34(a), this is notice that on May 6, 2010, Aptuit, 10245 Hickman
Mills Drive, Kansas City, Missouri 64137, made application by renewal
to the Drug Enforcement Administration (DEA) for registration as an
importer of the basic classes of controlled substances listed in
schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Marihuana (7360)........................... I
Poppy Straw Concentrate (9670)............. II
------------------------------------------------------------------------
The company plans to import a finished pharmaceutical product
containing cannabis extracts in dosage form for packaging for a
clinical trial study. In addition, the company also plans to import an
ointment for the treatment of wounds which contain trace amounts of the
controlled substances normally found in poppy straw concentrate for
packaging and labeling for clinical trials.
No comments, objections, or requests for any hearings will be
accepted on any application for registration or re-registration to
import crude opium, poppy straw, concentrate of poppy straw or coca
leaves. As explained in the Correction to Notice of Application
pertaining to Rhodes Technologies, 72 FR 3417 (2007), comments and
requests for hearings on applications to import narcotic raw material
are not appropriate.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances listed in schedule I or II, which fall under the authority
of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in
the circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR
1316.47.
Any such comments or objections should be addressed, in
quintuplicate,
[[Page 14689]]
to the Drug Enforcement Administration, Office of Diversion Control,
Federal Register Representative (ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be filed no later than April 15, 2011.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e), and (f). As noted in a previous notice published in the Federal
Register on September 23, 1975, (40 FR 43745-46), all applicants for
registration to import a basic class of any controlled substance in
schedule I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: March 8, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-6166 Filed 3-16-11; 8:45 am]
BILLING CODE 4410-09-P
